#obesity

Researchers traced semaglutide’s activity inside appetite-regulating neurons and found a molecular mechanism that may explain both strong responses and eventual plateaus.

New tracking from EPIC Research suggests rapid growth in GLP-1 prescribing has coincided with a small but sustained drop in obesity rates across a large medical-records dataset.

A phase 3b trial published in Nature Medicine found that daily oral orforglipron helped people maintain more of their prior weight loss after tirzepatide or semaglutide than placebo over 52 weeks.

European regulators have cleared Fractyl Health to begin what the source describes as the first clinical test of a GLP-1 gene therapy. The decision signals how aggressively drug developers are pursuing alternatives to长期?

A meta-analysis presented at the European Congress on Obesity suggests that roughly 8,500 daily steps may support long-term weight maintenance after dieting, addressing one of obesity treatment’s hardest problems.

Researchers at Helmholtz Munich have built a hybrid obesity therapy that uses GLP-1 and GIP signaling to deliver a second metabolic drug into target cells, producing stronger weight-loss and glucose effects in mice.

New work reported in Cell Metabolism suggests hormone-sensitive lipase has a second role inside adipocyte nuclei, helping explain why loss of the protein leads to lipodystrophy rather than obesity.

Researchers analyzing electronic health records from nearly 20 million patients report rapid growth in GLP-1 prescribing, even as many people with severe obesity still receive no treatment and bariatric surgery use slips

A large real-world analysis presented at ASMBS 2026 found that people with obesity and chronic kidney disease who underwent bariatric surgery had markedly lower risks of kidney failure, dialysis, cardiovascular events, и

A review of 11 major cardiovascular trials found GLP-1 receptor agonists were linked to fewer heart attacks, strokes, and cardiovascular deaths over nearly three years of follow-up, extending the case for the drugs wellb

A new study says the future risk of 18 obesity-related diseases can be predicted using 20 common health measures, suggesting that people with the same weight may face very different medical trajectories.

Researchers at Helmholtz Munich report a new treatment concept that combines GLP-1 and GIP signaling in a single hybrid molecule, with the goal of addressing obesity and type 2 diabetes together.

A 10-year study published in EMBO Reports suggests obesity can leave durable DNA methylation marks on helper T cells, potentially sustaining risk for obesity-related disease years after body weight improves.

A newly approved daily weight-loss pill moved through U.S. FDA review faster than most drugs in recent years, signaling continued momentum in the obesity treatment market.

A prespecified analysis of the SELECT trial found semaglutide reduced major adverse cardiovascular events in patients at elevated risk of substantial liver fibrosis while also lowering fatty liver index versus placebo.

A landmark analysis finds that modifiable risk factors — smoking, obesity, alcohol, diet, and environmental exposures — account for a large and preventable share of the global cancer burden.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Silicon Valley startup Twin Health is using continuous sensor data and artificial intelligence to build virtual replicas of patients' metabolisms, creating personalized treatment plans that have helped thousands reduce medications and reverse type 2 diabetes symptoms.

An oral compound from NTU Singapore reduces intestinal fat uptake and promotes beneficial gut bacteria without toxic side effects in animal models.